We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 210

Rochester Drug Coop., Inc. v. Braintree Labs., 712 F.Supp.2d 308 (D. Del. May 18, 2010)
  • Potter Anderson & Corroon LLP
  • USA
  • June 24 2011

In this action, plaintiffs asserted that defendant, which manufactured a drug called Miralax, violated Section 2 of the Sherman Act by engaging in a course of unlawful conduct that delayed the FDA’s approval of a competing generic drug, Glycolax.

PharmAthene, Inc. v. SIGA Technologies, Inc., C.A. No. 2627-VCP (Del. Ch. Nov. 23, 2010) (Vice Chancellor Parsons)
  • Potter Anderson & Corroon LLP
  • USA
  • November 30 2010

The Court of Chancery denied defendant’s motion for partial summary judgment because the plaintiff, PharmAthene, Inc. (“PharmAthene”), demonstrated a material issue of fact as to whether a term sheet it had entered into with defendant SIGA Technologies, Inc. (“SIGA”) constituted a binding licensing agreement.

Spotlight on unclaimed property: how Delaware turns $19,377 of unclaimed medical device property into $4.5 million of possible revenue
  • Baker Donelson Bearman Caldwell & Berkowitz PC
  • USA
  • October 15 2009

Distributors, manufacturers and sellers of pharmaceutical products and medical devices (and other Delaware-incorporated businesses having inventories) are alerted to the aggressive Delaware Division of Revenue's (Division) expanded unclaimed property audit focus on accrued, uninvoiced inventory.

Lisl J. Dunlop
  • Manatt Phelps & Phillips LLP

Ariel S. Wolf
  • Venable LLP